Core Insights - HeartFlow's stock price increased by 9% following endorsements from the American College of Cardiology (ACC) and the American Heart Association (AHA) for its technology [1][2][7] Group 1: Product Endorsements - HeartFlow's technology received endorsements from ACC and AHA, highlighting the importance of quantifying coronary plaque, which can be harmful [3][4] - The endorsements are expected to enhance the reputation and prominence of HeartFlow's HeartFlow Plaque Analysis product [7] Group 2: Financial Performance - HeartFlow's current market capitalization stands at $2.2 billion, with a stock price of $28.65 [5][8] - The stock's trading range for the day was between $27.45 and $29.82, with a 52-week range of $19.00 to $41.22 [8]

Core Insights - HeartFlow's stock experienced a 14% increase following FDA approval of its HeartFlow Plaque Analysis algorithm, despite the S&P 500 closing slightly negative [1][2] Product Development - The FDA granted approval for HeartFlow's HeartFlow Plaque Analysis, which is now available for sale [2][7] - The new version of the HeartFlow Plaque Analysis shows a 21% improvement in plaque detection compared to the first-generation product, utilizing data from approximately 273,000 patients [4] Market Impact - Cigna, a major health insurer, has updated its policies to cover the use of HeartFlow Plaque Analysis, effective October 1 [5]